BRANFORD, Conn., Nov. 21, 2017 /PRNewswire/ -- IsoCode, IsoPlexis Corporation's (IsoPlexis') single-cell precision platform, captured novel data from CAR-T products developed by Novartis Pharmaceuticals (Novartis), leading to IsoPlexis' development of new bioinformatics tools for visualizing high-dimensional, single-cell proteomics data. These new tools enable researchers to better compare key differences between products, and more easily analyze highly-multiplexed, single CAR-T cell functional profiles to gain insight into CAR-T product potency and cytokine mediated immuno-toxicity.
Researchers from IsoPlexis and Novartis published the results from their collaboration in the November issue of the Journal for ImmunoTherapy of Cancer.
IsoCode, IsoPlexis' next-generation platform developed to detect cellular responses at the single-cell level, can capture a previously unseen 42 different secreted proteins per cell, across thousands of single cells simultaneously. The result is a precise functional profile of tumor-reactive T cells in each patient, which enables researchers to better predict and understand complex cancer patient response.
Researchers used IsoCode to analyze genetically re-engineered CAR-T cells designed to target CD19, a promising treatment for B-cell malignancies, including most cases of non-Hodgkin lymphoma and some types of leukemia. Using IsoCode, IsoPlexis and Novartis researchers captured new biomarker data from these CD19-targeting T cells across multiple donors.
The large quantity of precise, high-quality data required IsoPlexis to develop new bioinformatics tools, which researchers used to better visualize the polyfunctional profiles of each individual CAR-T product. These tools, which include Polyfunctional Activation Topology Principal Component Analysis (PAT PCA) and polyfunctional heat maps, have allowed researchers to intuitively compare products from different donors, and visualize the key combinations of proteins being secreted on a single-cell level in each product.
"Through our work with our key collaborators, we were able to further the process of understanding how CAR-T cells respond to their targets," said Sean Mackay, IsoPlexis CEO and Co-Founder. "Using our next-generation platform, we captured new product biomarker data and developed new tools to understand the data, which can help researchers improve future products for patients who need them the most."
Rong Fan, Ph.D., IsoPlexis Co-Founder and Scientific Advisory Board Chair, an Associate Professor of Biomedical Engineering at Yale University, and the inventor of the original single-cell multi-protein analysis technology, said, "These findings reveal a complex, yet meaningful, landscape of immune effector response in CD19 CAR-T cells," adding, "IsoPlexis technology enables us to assess CAR-T product pre-infusion, and potentially teach us how to engineer CAR-T cells with more efficacious and less immuno-toxic profiles."
IsoPlexis, a privately held life sciences company, is developing novel technologies at the forefront of the revolution in immunity-based treatments of cancer. Using a next-generation diagnostic and therapeutic platform to identify patient responses at the single-cell level, IsoPlexis' original scientific leaders from Yale, Caltech, UCLA, and Memorial Sloan Kettering Cancer Center have advanced understandings of personalized therapies against various cancers. IsoPlexis is venture funded by Spring Mountain Capital, North Sound Ventures, and Connecticut Innovations, as well as supported through grant funding from the National Cancer Institute and the National Institutes of Health. For additional information on IsoPlexis, visit http://www.isoplexis.com or email email@example.com.
SOURCE IsoPlexis Corporation